Meredith Ann-Marie, Dass Crispin R
School of Pharmacy, Curtin University, Bentley, WA, Australia.
Curtin Biosciences Research Precinct, Bentley, WA, Australia.
J Pharm Pharmacol. 2016 Jun;68(6):729-41. doi: 10.1111/jphp.12539. Epub 2016 Mar 14.
The use of doxorubicin, a drug utilised for many years to treat a wide variety of cancers, has long been limited due to the significant toxicity that can occur not only during, but also years after treatment. It has multiple mechanisms of action including the intercalation of DNA, inhibition of topoisomerase II and the production of free radicals. We review the literature, with the aim of highlighting the role of drug concentration being an important determinant on the unfolding cell biological events that lead to cell stasis or death.
The PubMed database was consulted to compile this review.
It has been found that the various mechanisms of action at the disposal of doxorubicin culminate in either cell death or cell growth arrest through various cell biological events, such as apoptosis, autophagy, senescence and necrosis. Which of these events is the eventual cause of cell death or growth arrest appears to vary depending on factors such as the patient, cell and cancer type, doxorubicin concentration and the duration of treatment.
Further understanding of doxorubicin's influence on cell biological events could lead to an improvement in the drug's efficacy and reduce toxicity.
多柔比星用于治疗多种癌症已有多年,但长期以来其应用受到限制,因为不仅在治疗期间,而且在治疗后的数年都可能出现显著毒性。它具有多种作用机制,包括嵌入DNA、抑制拓扑异构酶II以及产生自由基。我们回顾文献,旨在强调药物浓度作为导致细胞停滞或死亡的细胞生物学事件发展的重要决定因素所起的作用。
查阅PubMed数据库以编写本综述。
已发现多柔比星可用的各种作用机制通过各种细胞生物学事件,如凋亡、自噬、衰老和坏死,最终导致细胞死亡或细胞生长停滞。这些事件中哪一个是细胞死亡或生长停滞的最终原因似乎因患者、细胞和癌症类型、多柔比星浓度以及治疗持续时间等因素而异。
进一步了解多柔比星对细胞生物学事件的影响可能会提高该药物的疗效并降低毒性。